Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__


{{Reteplase}}
{{Antithrombin III}}


{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{JH}}


'''''For patient information, click <u>[[Reteplase (patient information)|here]]'''''</u>.
'''''For patient information, click <u>[[Antithrombin III (patient information)|here]]'''''</u>.
{{SB}} Retavase<sup>®</sup>


==Overview==
==Overview==
'''Reteplase''' (trade names '''Retavase''', '''Rapilysin''') is a [[thrombolytic drug]], used to treat [[myocardial infarction|heart attacks]] by breaking up the [[clot]]s that cause them. 


Reteplase is a recombinant non-glycosylated form of human [[tissue plasminogen activator]], which has been modified to contain 357 of the 527 [[amino acid]]s of the original [[protein]]. It is produced in the [[bacterium]] [[Escherichia coli]].{{citation needed|date=December 2013}}
==Category==


Reteplase is similar to recombinant human tissue plasminogen activator ([[alteplase]]), but the modifications give reteplase a longer [[half-life]] of 13–16 minutes.  Reteplase also binds [[fibrin]] with lower affinity than alteplase, improving its ability to penetrate into clots.
==US Brand Names==
'''THROMBATE III'''<sup>®</sup>


Reteplase was approved by the [[Food and Drug Administration]] in 1996.
==FDA Package Insert==


==Category==
'''| [[Antithrombin III indications and usage|Indications and Usage]]'''
[[Thrombolytics]], tissue plasminogen activators.
'''| [[Antithrombin III dosage and administration|Dosage and Administration]]'''
==FDA Package Insert==
'''| [[Antithrombin III dosage forms and strengths|Dosage Forms and Strengths]]'''
===Retavase<sup>®</sup>===
'''| [[Antithrombin III contraindications|Contraindications]]'''
''' [[Reteplase indications and usage|Indications and Usage]]'''
'''| [[Antithrombin III warnings|Warnings and Precautions]]'''
'''| [[Reteplase dosage and administration|Dosage and Administration]]'''
'''| [[Antithrombin III adverse reactions|Adverse Reactions]]'''
'''| [[Reteplase dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Antithrombin III drug interactions|Drug Interactions]]'''
'''| [[Reteplase contraindications|Contraindications]]'''
'''| [[Antithrombin III use in specific populations|Use in Specific Populations]]'''
'''| [[Reteplase warnings and precautions|Warnings and Precautions]]'''
'''| [[Antithrombin III overdosage|Overdosage]]'''
'''| [[Reteplase adverse reactions|Adverse Reactions]]'''
'''| [[Antithrombin III description|Description]]'''
'''| [[Reteplase drug interactions|Drug Interactions]]'''
'''| [[Antithrombin III clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Reteplase use in specific populations|Use in Specific Populations]]'''
'''| [[Antithrombin III nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Reteplase overdosage|Overdosage]]'''
'''| [[Antithrombin III clinical studies|Clinical Studies]]'''
'''| [[Reteplase description|Description]]'''
'''| [[Antithrombin III how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Reteplase clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Antithrombin III patient counseling information|Patient Counseling Information]]'''
'''| [[Reteplase nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Antithrombin III labels and packages|Labels and Packages]]'''
'''| [[Reteplase clinical studies|Clinical Studies]]'''
'''| [[Reteplase how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Reteplase patient counseling information|Patient Counseling Information]]'''
'''| [[Reteplase labels and packages|Labels and Packages]]'''


==Mechanism of Action==
==Mechanism of Action==
Retavase® is a recombinant [[plasminogen activator]] which catalyzes the cleavage of endogenous [[plasminogen]] to generate [[plasmin]]. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.1,2In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in [[fibrinogen]] levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 unit) in which 10 units (17.4 mg) was followed 30 minutes later by a second bolus of 10 units (17.4 mg).3 The mean fibrinogen level returned to the baseline value by 48 hours.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher =  | date =  |accessdate =  }}</ref>


==References==
==References==
{{Cite web  | last =  | first =  | title = THROMBATE III (ANTITHROMBIN III) KIT [GRIFOLS USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2a9f856-3ef7-8da4-920c-f738e4f1f7d7 | publisher =  | date =  | accessdate = 7 March 2014 }}


{{Reflist|2}}
{{Reflist|2}}
[[Category: cardiovascular Drugs]]
 
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 14:37, 8 July 2014


Antithrombin III
THROMBATE III® FDA Package Insert
Indications and Usage
Dosage and Administration
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Description
Clinical Pharmacology
How Supplied/Storage and Handling

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

For patient information, click here.

Overview

Category

US Brand Names

THROMBATE III®

FDA Package Insert

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

"THROMBATE III (ANTITHROMBIN III) KIT [GRIFOLS USA, LLC]". Retrieved 7 March 2014.

Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox/AL&oldid=990166"